Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ObsEva SA is a biotechnology business based in the US. ObsEva shares (OBSV) are listed on the NASDAQ and all prices are listed in US Dollars. ObsEva employs 48 staff and has a trailing 12-month revenue of around $4.8 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $0.14 |
|---|---|
| 52-week range | $0.13 - $3.25 |
| 50-day moving average | $0.45 |
| 200-day moving average | $1.34 |
| Wall St. target price | $4.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.64 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.1421 from 2022-09-30
| 1 week (2022-09-23) | 0.78% |
|---|---|
| 1 month (2022-09-01) | -19.99% |
| 3 months (2022-07-01) | -91.93% |
| 6 months (2022-04-01) | -90.65% |
| 1 year (2021-10-01) | -95.42% |
|---|---|
| 2 years (2020-10-01) | -94.08% |
| 3 years (2019-10-01) | 8.1 |
| 5 years (2017-09-29) | 8.14 |
| Revenue TTM | $4.8 million |
|---|---|
| Gross profit TTM | $17,000 |
| Return on assets TTM | -36.7% |
| Return on equity TTM | -323.01% |
| Profit margin | 0% |
| Book value | $0.33 |
| Market capitalisation | $11.9 million |
TTM: trailing 12 months
We're not expecting ObsEva to pay a dividend over the next 12 months.
ObsEva's shares were split on a 13:1 basis on 5 December 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 13 shares. This wouldn't directly have changed the overall worth of your ObsEva shares – just the quantity. However, indirectly, the new 92.3% lower share price could have impacted the market appetite for ObsEva shares which in turn could have impacted ObsEva's share price.
Over the last 12 months, ObsEva's shares have ranged in value from as little as $0.13 up to $3.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ObsEva's is 0.2845. This would suggest that ObsEva's shares are less volatile than average (for this exchange).
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.